Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Research

Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4

Authors: Jihua Nie, Jingying Zhang, Lili Wang, Lunjie Lu, Qian Yuan, Fangmei An, Shuyu Zhang, Yang Jiao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

The early occurrence regional nodal and distant metastases cholangiocarcinoma (CCA) is one of the major reasons for its poor prognosis. However, the related mechanisms are largely elusive. Recently, increasing evidences indicate that adipocytes might be involved in the proliferation, homing, migration and invasion of several malignancies. In the present study, we attempt to determine the effects and possible mechanisms of adipocytes on regulating progression of CCA.

Methods

Adipocyte–CCA cell co-culture system and CCA metastasis mice model were used to determine the effects of adipocytes on CCA metastasis. We identified the biological functions and possible mechanisms of adipocyte-derived fatty acid binding protein 4 (FABP4) in regulating the adipocyte-induced CCA metastasis and epithelial-mesenchymal transition (EMT) phenotypes, both in vitro and in vivo.

Results

Adipocyte–CCA cell co-culture promotes the in vitro and in vivo tumor metastasis, leading to increased adipocyte-derived fatty acid absorbance and intracellular lipids of CCA cells, which indicates adipocytes might function as the energy source for CCA progression by providing free fatty acids. Further, highly expressed FABP4 protein was identified in adipose tissues and fully differentiated adipocytes, and upregulated FABP4 was also detected by qRT-PCR assay in CCA cells co-cultivated with adipose extracts as compared to parental CCA cells. The specific FABP4 inhibitor BMS309403 significantly impaired adipocyte-induced CCA metastasis and EMT phenotypes both in vitro and in vivo.

Conclusions

Together, the results demonstrate that the adipocyte-CCA interaction and the energy extraction of CCA cells from adipocytes are crucial for the invasion, migration and EMT of CCA cells. FABP4 from adipocytes mediates these adipocyte-induced variations in CCA cells, which could serve as a potential target for the treatment of CCA.

Available only for authorised users

Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–79. doi:10.1016/S0140-6736(13)61903-0.CrossRefPubMedPubMedCentral

Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–44. doi:10.1053/j.gastro.2009.02.038.CrossRefPubMed

Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10:77–82. doi:10.1080/13651820801992641.CrossRef

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H. British Society of G. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69. doi:10.1136/gutjnl-2011-301748. CrossRefPubMed

Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531–40. doi:10.1200/JCO.2009.27.4787.CrossRefPubMedPubMedCentral

Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189–200. https://doi.org/10.1038/nrgastro.2011.20. CrossRefPubMedPubMedCentral

Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-mesenchymal transition and cancer invasiveness: what can we learn from cholangiocarcinoma? J Clin Med. 2015;4:2028–41. doi:10.3390/jcm4121958.CrossRefPubMedPubMedCentral

Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–25. doi:10.1038/sj.bjc.6604129.CrossRefPubMed

Oyasiji T, Zhang J, Kuvshinoff B, Iyer R, Hochwald SN. Molecular targets in biliary carcinogenesis and implications for therapy. Oncologist. 2015;20:742–51. https://doi.org/10.1634/theoncologist.2014-0442.CrossRefPubMedPubMedCentral

10.

Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 2005;18:412–20. https://doi.org/10.1038/modpathol.3800287.CrossRefPubMed

11.

Lee S, Kim WH, Jung HY, Yang MH, Kang GH. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol. 2002;161:1015–22. https://doi.org/10.1016/S0002-9440(10)64262-9.CrossRefPubMedPubMedCentral

12.

Tischoff I, Wittekind C, Tannapfel A. Role of epigenetic alterations in cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg. 2006;13:274–9. doi:10.1007/s00534-005-1055-3.CrossRef

13.

Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch Pathol Lab Med. 2007;131:923–30. https://doi.org/10.1043/1543-2165(2007)131[923:MPOMCI]2.0.CO;2. PubMed

14.

Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics. 2010;2:233–43.doi: 10.2217/epi.10.9.CrossRefPubMedPubMedCentral

15.

Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:84. doi:10.1186/s13058-016-0740-2.CrossRefPubMedPubMedCentral

16.

Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–95. doi:10.1038/nrc3174.CrossRefPubMed

17.

Varmus H, Harlow E. Science funding: provocative questions in cancer research. Nature. 2012;481:436–7. doi:10.1038/481436a.CrossRefPubMed

18.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503. doi:10.1038/nm.2492.CrossRefPubMedPubMedCentral

19.

Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta. 2011;1807:664–78. doi:10.1016/j.bbabio.2010.11.004.CrossRefPubMed

20.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90. doi:10.1016/j.cell.2009.11.007.CrossRefPubMed

21.

Vaquero J, Guedj N, Claperon A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L. Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks. J Hepatol. 2017;66:424–41. doi:10.1016/j.jhep.2016.09.010.CrossRefPubMed

22.

Iser IC, Ceschini SM, Onzi GR, Bertoni AP, Lenz G, Wink MR. Conditioned medium from adipose-derived stem cells (ADSCs) promotes epithelial-to-mesenchymal-like transition (EMT-like) in glioma cells in vitro. Mol Neurobiol. 2016;53:7184–99. https://doi.org/10.1007/s12035-015-9585-4.CrossRefPubMed

23.

Lee Y, Jung WH, Koo JS. Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res Treat. 2015;153:323–35. doi:10.1007/s10549-015-3550-9.CrossRefPubMed

24.

Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, Shiraishi R, Sakata Y, Tsunada S, Iwakiri R, Fujimoto K. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol. 2007;292:G923–9. doi:10.1152/ajpgi.00145.2006. CrossRefPubMed

25.

Tan J, Buache E, Chenard MP, Dali-Youcef N, Rio MC. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol. 2011;55:851–9. doi: 10.1387/ijdb.113365jt.CrossRefPubMed

26.

Fletcher SJ, Sacca PA, Pistone-Creydt M, Colo FA, Serra MF, Santino FE, Sasso CV, Lopez-Fontana CM, Caron RW, Calvo JC, Pistone-Creydt V. Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer. J Exp Clin Cancer Res. 2017;36:26. doi:10.1186/s13046-017-0494-4.CrossRefPubMedPubMedCentral

27.

Ito R, Narita S, Huang M, Nara T, Numakura K, Takayama K, Tsuruta H, Maeno A, Saito M, Inoue T, Tsuchiya N, Satoh S, Habuchi T. The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: a potential mechanism for the "obesity paradox". PLoS One. 2017;12:e0171615. doi:10.1371/journal.pone.0171615.CrossRefPubMedPubMedCentral

28.

Zi X, Lusch A, Blair CA, Okhunov Z, Yokoyama NN, Liu S, Baker M, Huynh V, Landman J. Effect of perineoplasm perinephric adipose tissues on migration of clear cell renal cell carcinoma cells: a potential role of WNT signaling. Oncotarget. 2016;7:53277–88. 10.18632/oncotarget.10467.CrossRefPubMedPubMedCentral

29.

Li JS, Han TJ, Jing N, Li L, Zhang XH, Ma FZ, Liu JY. Obesity and the risk of cholangiocarcinoma: a meta-analysis. Tumour Biol. 2014;35:6831–8. doi:10.1007/s13277-014-1939-4.CrossRefPubMed

30.

Jiao Y, Zhang J, Lu L, Xu J, Qin L. The Fto gene regulates the proliferation and differentiation of pre-adipocytes in vitro. Nutrients. 2016;8:102. doi:10.3390/nu8020102.CrossRefPubMedPubMedCentral

31.

Jiao Y, Liu C, Cui FM, JY X, Tong J, Qi XF, Wang LL, Zhu W. Long intergenic non-coding RNA induced by X-ray irradiation regulates DNA damage response signaling in the human bronchial epithelial BEAS-2B cell line. Oncol Lett. 2015;9:169–76. doi:10.3892/ol.2014.2622. PubMed

32.

Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71:2455–65. doi:10.1158/0008-5472.CAN-10-3323.CrossRefPubMed

33.

Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, et al. Platelet-derived growth factor-D and rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013;58:1042–53. doi:10.1002/hep.26384.CrossRefPubMedPubMedCentral

34.

Jiang L, Deberardinis R, Boothman DA. The cancer cell 'energy grid': TGF-beta1 signaling coordinates metabolism for migration. Mol Cell Oncol. 2015;2:e981994. https://doi.org/10.4161/23723556.2014.981994.CrossRefPubMedPubMedCentral

35.

Bosy-Westphal A, Kahlhofer J, Lagerpusch M, Skurk T, Muller MJ. Deep body composition phenotyping during weight cycling: relevance to metabolic efficiency and metabolic risk. Obes Rev. 2015;16(Suppl 1):36–44. doi:10.1111/obr.12254. CrossRefPubMed

36.

Zamboni M, Rossi AP, Fantin F, Zamboni G, Chirumbolo S, Zoico E, Mazzali G. Adipose tissue, diet and aging. Mech Ageing Dev. 2014;136-137:129–37. doi:10.1016/j.mad.2013.11.008.CrossRefPubMed

37.

Matafome P, Santos-Silva D, Sena CM, Seica R. Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes Metab Res Rev. 2013;29:285–95. doi:10.1002/dmrr.2395.CrossRefPubMed

38.

Gong Y, Dou LJ, Liang J. Link between obesity and cancer: role of triglyceride/free fatty acid cycling. Eur Rev Med Pharmacol Sci. 2014;18:2808–20.PubMed

39.

Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: is there a role of fatty acid metabolism? Biomed Res Int. 2015;2015:274585. doi:10.1155/2015/274585.CrossRefPubMedPubMedCentral

40.

Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503. doi:10.1038/nrd2589.CrossRefPubMedPubMedCentral

41.

Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11:592–605. doi:10.1038/nrendo.2015.122.CrossRefPubMedPubMedCentral

42.

Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32:550–70. doi:10.1210/er.2010-0030.CrossRefPubMedPubMedCentral

43.

Xiong Y, McDonald LT, Russell DL, Kelly RR, Wilson KR, Mehrotra M, Soloff AC, LaRue AC. Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment. World J Stem Cells. 2015;7:253–65. doi:10.4252/wjsc.v7.i2.253.CrossRefPubMedPubMedCentral

44.

Wang C, Gao C, Meng K, Qiao H, Wang Y. Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. PLoS One. 2015;10:e0119348. doi:10.1371/journal.pone.0119348.CrossRefPubMedPubMedCentral

45.

Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009;182:1621–7. doi:10.1016/j.juro.2009.06.015.CrossRefPubMed

46.

Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, Gromova I. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics. 2005;4:492–522. doi:10.1074/mcp.M500030-MCP200.CrossRefPubMed

47.

Pistone Creydt V, Fletcher SJ, Giudice J, Bruzzone A, Chasseing NA, Gonzalez EG, Sacca PA, Calvo JC. Human adipose tissue from normal and tumoral breast regulates the behavior of mammary epithelial cells. Clin Transl Oncol. 2013;15:124–31. doi:10.1007/s12094-012-0896-x.CrossRefPubMed

48.

Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16:488–94. doi:10.1038/ncb2976.CrossRefPubMed

49.

Lamouille S, Subramanyam D, Blelloch R, Derynck R. Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol. 2013;25:200–7. https://doi.org/10.1016/j.ceb.2013.01.008.CrossRefPubMedPubMedCentral

50.

Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491:364–73. doi:10.1038/nature11706.CrossRefPubMed

51.

Currie E, Schulze A, Zechner R, Walther TC, Farese RVJ. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61. doi:10.1016/j.cmet.2013.05.017.CrossRefPubMedPubMedCentral

52.

Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012;2:328–43. doi:10.1158/2159-8290.CD-11-0234.CrossRefPubMed

53.

Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV, Zaidi N. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One. 2014;9:e106913. doi:10.1371/journal.pone.0106913.CrossRefPubMedPubMedCentral

54.

Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831:1533–41. https://doi.org/10.1016/j.bbalip.2013.02.010.CrossRefPubMedPubMedCentral

55.

Hu J, Liu Z, Wang X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med Hypotheses. 2013;81:515–20. https://doi.org/10.1016/j.mehy.2013.06.009.CrossRefPubMed

56.

Nath A, Li I, Roberts LR, Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752. https://doi.org/10.1038/srep14752.CrossRefPubMedPubMedCentral

57.

Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care. 2014;17:124–9. doi:10.1097/MCO.0000000000000031.CrossRefPubMed

58.

Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, Inouye K, Rickey LM, Ercal BC, Furuhashi M, Tuncman G, Hotamisligil GS. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 2013;17:768–78. doi:10.1016/j.cmet.2013.04.012.CrossRefPubMedPubMedCentral

59.

Uehara H, Takahashi T, Oha M, Ogawa H, Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer. 2014;135:2558–68. doi:10.1002/ijc.28903.CrossRefPubMed

Title: Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4
Authors: Jihua Nie
Jingying Zhang
Lili Wang
Lunjie Lu
Qian Yuan
Fangmei An
Shuyu Zhang
Yang Jiao
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0641-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1

Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer

Retraction Note: MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling

ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population

Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer

Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer